Global Preimplantation Genetic Testing Market Research Report: Information by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2027
Market Highlights
It is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.
Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes. Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.
The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age. This leads to the growth of the preimplantation genetic testing market during the forecast period. According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5, which is 3% less, this shows the reduction in the rate of fertility.
An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing market
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8121
Segmentation
The global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.
The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). Hundred different genetic conditions can be tested with Preimplantation Genetic Diagnosis (PGD) which enables the couple to have a baby with no genetic defect thus the segment is expected to hold the largest market share owing to rising awareness population and healthcare experts. Preimplantation Genetic Screening (PGS) segment is also anticipated to grow profitably to increase healthy pregnancy.
By type, embryo testing segment is expected to show favorable growth as the threat of chromosomal abnormalities increases. By product and service, the reagents and consumables segment anticipated to hold the largest market share as there is continuous declination infertility of female due to increasing usage of reagents for the diagnosis. By technology, the next-generation sequencing segment, and comparative genomic hybridization also expected to hold large share as its cost is reduced and its capability to detect mosaicism. The market by end user has been segmented into maternity centers & fertility clinics
hospitals, diagnostic labs and research laboratories & academic institutes. Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Key Players
Some of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The global preimplantation genetic testing market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European global preimplantation genetic testing market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The global preimplantation genetic testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/preimplantation-genetic-testing-market-8121
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
The Preimplantation Genetic Testing Market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute, Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc., Oxford Gene Technology.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Preimplantation Genetic Testing Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/preimplantation-genetic-testing-market/download-sampleMarket DynamicsThe global foot-operated control panel for the elevator market is projected to grow at a significant pace during the forecast period.
A foot-operated control panel was invented with a concern towards a disabled person.
But soon, the picture is predicted to be changing.
According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Browse and in-depth TOC on " Preimplantation Genetic Testing Market "85 - Tables42 - Figures204- PagesDownload PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=605By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016 Geographically, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America accounted for the largest share of the market in 2016, followed by Europe.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the Preimplantation Genetic Testing Market in North America.Talk To Our Research Analysts: -http://www.marketsandmarkets.com/speaktoanalyst.asp?id=605As of 2016, the major product manufacturers operating in the global Preimplantation Genetic Testing Market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).
